SHANGHAI, March 18, 2022 / PRNewswire / – At present COVID-19 is still in pandemic status around the world. The superposition of Delta and Omicron variants is widespread, resulting in a continuous improvement in their transmission capability. In the midst of the repeated waves of COVID-19, the development of effective oral COVID-19 drugs and rapid, simple and innovative testing methods, in addition to the COVID-19 vaccine, has also become a new requirement for current epidemic prevention and control. Viva Biotech Holdings (share code: 1873.HK, hereinafter referred to as “Viva Biotech”) and XLement, invested and incubated by Viva BioInnovator, are committed to producing oral COVID-19 drugs and virus testing, contributing to the fight against COVID 19-pandemic.
Langhua Pharmaceutical signs agreement with MPP to produce raw ingredient of COVID-19 antiviral drug molnupiravir
January 2022, Medicines Patent Pool (MPP) announced that it has signed agreements with several generic manufacturing companies, including Zhejiang Langhua Pharmaceutical Co., Ltd (Langhua Pharmaceutical), the subsidiary of Viva biotech holdings (Viva Biotech (01873.HK)) for the manufacture of the oral COVID-19 antiviral drugs molnupiravir and supply in 105 low- and middle-income countries (LMICs) to facilitate affordable global access for molnupiravir and support local prevention and control of epidemics. Five companies will focus on producing the raw materials, 13 companies will produce both the raw ingredient and the finished drug and 9 companies will produce the finished drug.
Medicines Patent Pool (MPP) is a UN-funded public health organization working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. MPP and MSD, the trade name of Merck & Co., Inc. Kenilworth NJ USA signed a voluntary licensing agreement in October 2021. Under the terms of the agreement, MPP, through the license granted by MSD, will be authorized to further license non-exclusive sub-licenses to manufacturers (“MPP license”) and to diversify the production basis for the supply of quality assured molnupiravir to the countries covered by the MPP license. subject to the approval of local authorities.
Molnupiravir (MK-4482 and EIDD-2801) is an experimental, orally administered form of a potent ribonucleoside analogue that inhibits the replication of SARS-CoV-2 (the causative agent of COVID-19). Molnupiravir, which MSD is developing in collaboration with Ridgeback Biotherapeutics, is the first oral antiviral drug available for COVID-19 treatment. Data from phase 3 MOVE-OUT showed that early treatment with molnupiravir significantly reduced the risk of hospitalization or high-risk death in unvaccinated adults with COVID-19.
According to MPP, the companies that were offered the sublicense have successfully demonstrated their ability to meet MPP’s requirements regarding production capacity, compliance with the law and the ability to meet international standards for quality-assured medicines. The approval granted to Langhua Pharmaceutical by MPP represents a high degree of confirmation and recognition in its process development and strengthening of APIs, supply sustainability, GMP and EHS system.
Xlement’s COVID-19 test kit successfully passed the inspection of the Ministry of Science and Technology of the People’s Republic of China
On March 2, 2022Xlement, a dedicated NanoSPR biochip and instruments biotech company that has previously invested and incubated by Viva BioInnovator, received the announcement to pass the performance evaluation from the Ministry of Science and Technology for the People China. Its project “R&D and mass production of NanoSPR COVID-19 particle test kits” is one of the key projects in the program “Public Safety Risk Prevention and Control and Emergency Response Technology and Equipment”, which serves a significant part of the key COVID-19-related scientific research in progress in China. With its successful review for the inspection, the Xlements COVID-19 Test Kit has also been certified by the EU CE for future massive production and will soon be put into use.
Utilized on the unique NanoSPR chip technology, Xlement developed the test kit for COVID-19 particles, which allows one-step testing of multiple virus antigens for 96 samples within 15 minutes, and the sensitivity is close to testing a single antigen. This method shows great advantages compared to existing viral nucleic acid testing techniques: it can be used for self-testing at home, it shortens the test time significantly and thus reduces the cost of testing reagents and labor significantly. With more use of the NanoSPR technology in the COVID-19 test developed by Xlement, we expect to see more convenient immediate diagnosis of suspected samples and rapid on-site screening on a large scale.
About Viva Biotech Holdings
Since its inception in 2008, Viva Biotech (01873.HK) has always adhered to the mission of “becoming the cradle of global innovative biotech companies from around the world” and provided one-stop services for research and development and production of drugs to global biopharmaceutical innovators. By leveraging the technical benefits of Structure-based Drug Discovery (SBDD), we deliver leading CRO drug discovery services and CMC / CDMO services throughout the drug production process to global biopharmaceutical customers. At the same time, we focus on finding and investing in high-potential biotech start-ups, solving unmet clinical medical needs in the form of EFS (service for equity) and continuing to build an open collaboration platform and win-win ecosystem for biotech innovation.
About Langhua Pharmaceutical
Zhejiang Langhua Pharmaceutical Co., Ltd., is a comprehensive enterprise engaged in research and development, production of pharmaceutical products. As a subsidiary of the world’s leading drug discovery CRO company Viva biotech holdings, Langhua offers our worldwide partners One-Stop CDMO solution in new drug full life cycle for small molecules Active Pharmaceutical Ingredients (APIs) and finished dosage forms, from preclinical to commercial offering.
Liangzhun (XLement) focuses on developing innovative biological detection chips and similar equipment products using its unique sensor chip design and manufacturing patent technology that can be used as life science tools, detection reagents and equipment for biomedical research and in vitro clinical medical diagnostics. With the obvious benefits of excellent cost performance, the NanoSPR chip has broken the monopoly of imported test products and applied in a wider range of biomedical R&D areas, helping the independent innovation and development of the biomedical technology industry. The company now operates in several cities in China including Shanghai, Wuhanand Hangzhou for specific research and production.
SOURCE Viva Biotech